Back to Archived News
Power3 Medical Products, Inc. Files Two Patent Applications for Parkinson’s Disease
Wednesday, September 19, 2007
Houston, TX -- Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, has filed two Utility Patent Applications with the U.S. Patent and Trademark Office. The two patents are for a number of the Company’s identified blood serum protein biomarkers, part of Power3’s clinically validated biomarker panel for early detection and differential diagnosis of Parkinson’s disease.
Parkinson’s disease is the second most common neurodegenerative disease in adults, inflicting 1.5 million people in the U.S. Currently, there are no clinical diagnostic tests in the market for early diagnosis or drug targets for treatment of neurodegenerative diseases such as Parkinson’s disease.
In the early stages of Parkinson’s disease, it is difficult for physicians to differentiate the disease from other similar clinical disorders. For this reason, there is a lack of specificity in clinical diagnoses, until further characteristic signs and symptoms appear by the progression of the disease to incurable stages.
Dr. Ira L. Goldknopf, director of proteomics for Power3 Medical comments, "The specificity for early diagnosis of Parkinson’s disease is very important for early treatment. The biomarkers involved in these patent applications have demonstrated unique specificities for Parkinson’s disease. When used in combination with other Parkinson’s biomarkers in our diagnostic panel, they increase the accuracy of diagnostic specificity to distinguish Parkinson’s patients from other similar neurological disorders."
Steven Rash, Chairman and Chief Executive Officer of Power3 Medical continues, "By monitoring the blood serum concentrations of these biomarkers, as well as additional biomarkers, which Power3 uses in our NuroPro® blood serum tests, we intend to usher in a new era of highly specific blood-based diagnostic tests for Parkinson’s and related neurodegenerative diseases. We continue to move forward in our commercialization efforts as well as strengthening our intellectual property portfolio, which currently includes fifteen patents pending and numerous other patent applications in the pipeline."
About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas, and recently announced an agreement forming a joint venture (CRO) with NeoGenomics, Inc. (Nasdaq: NGNM) of Fort Myers, Florida, to commercialize Power3’s portfolio of IP, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s and Parkinson’s Diseases.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
Back to Archived News
